Abstract
An invitational conference was held to plan a therapeutic interchange program for biotechnology products. The expanding use of biotechnology products has created new challenges and opportunities for organizations who want to implement these programs — with the dual goal of cutting costs and improving quality of care. Successful therapeutic interchange programs can use a variety of strategies, from gentle persuasion based on clinical effectiveness and cost savings to mandatory compliance and automatic substitution. After outlining risk-management considerations and motivations, as well as the barriers to the therapeutic interchange of biotechnology products, the participants identified the following key steps: (1) list biotechnology products that are potential candidates for therapeutic interchange; (2) establish an overall plan for therapeutic interchange programs; (3) select the specific biotechnology products that will be considered for therapeutic interchange; (4) devise a strategy for therapeutic interchange of the selected products; (5) implement the plan; and (6) track program success. The strategy must include a process for ongoing monitoring of clinical and economic outcomes to ensure that the program is meeting its objectives and provide feedback to program participants.
Keywords
Get full access to this article
View all access options for this article.